ARTICLE | Company News
TXN licenses anti-cancer protein
March 5, 2001 8:00 AM UTC
TranXenoGen (LSE:TXN) received an exclusive global license for human anti-neoplastic urinary protein form Antitumor Research Products (Memphis, Tenn.). Antitumor Research receives upfront and mileston...